S
SRPT
Sarepta Therapeutics Inc
18.79
-0.43-2.24%After Hours: 19.00 +0.21 +1.12%19:34 08/21 EDT
OPEN/PREV CLOSE19.39/19.22
TODAY RANGE18.66-19.73
VOL1.67M
MARKET CAP1.98B
52 WEEK RANGE14.68-25.32
AVG VOL (3M)3.32M
% TURNOVER1.59%
TURNOVER--
P/E (TTM)-11.3084
% RANGE5.57%
EPS(TTM)-1.6616
P/E(FORWARD)6.02
P/B1.299
BVPS14.46
DIVIDEND--
P/S0.8972
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP1.89B
SHARES OUTSTANDING105.63M
NEXT EARNINGS11/02-11/06
FREE FLOAT100.42M
LOT SIZE1
EX-DATE07/12/2012
News
Press Releases
Financial Reports
Profile
Simply Wall St·08/13 20:20
Sarepta Therapeutics (SRPT) Tightened 2026 Revenue Guidance, Is The Stock Still A Bargain?
TipRanks·08/10 12:45
Evercore ISI Reaffirms Their Hold Rating on Sarepta Therapeutics (SRPT)
Simply Wall St·08/10 05:30
Why Sarepta Therapeutics (SRPT) Is Up 12.9% After Cutting 2026 Guidance And Naming A New CEO
Simply Wall St·08/08 10:33
Sarepta Therapeutics (SRPT) Brings In Michael Severino As Chief Executive Officer
TipRanks·08/07 13:40
Unusually active option classes on open August 7th
TipRanks·08/07 08:48
Barclays Reaffirms Their Hold Rating on Sarepta Therapeutics (SRPT)
TipRanks·08/07 00:04
Sarepta Therapeutics Balances Profit Gains With Revenue Strain
Simply Wall St·08/06 23:43
Sarepta Therapeutics (SRPT) Stock Rally Hinges On Profit Progress And Revenue Drop
TipRanks·08/06 13:16
Cantor Fitzgerald Keeps Their Hold Rating on Sarepta Therapeutics (SRPT)
TipRanks·08/06 12:28
Sarepta price target lowered to $35 from $37 at Oppenheimer
TipRanks·08/06 11:37
Wedbush Keeps Their Buy Rating on Sarepta Therapeutics (SRPT)
TipRanks·08/06 11:19
Wells Fargo Remains a Buy on Sarepta Therapeutics (SRPT)
TipRanks·08/06 11:18
Morgan Stanley Keeps Their Hold Rating on Sarepta Therapeutics (SRPT)